NeoGenomics outlines revised 2025 outlook with 9%-10% revenue growth target amid pharma headwinds and PanTracer launch NeoGenomics outlines revised 2025 outlook with 9%-10% revenue growth target amid pharma headwinds and PanTracer launch Post ContentneoRead More You might also be interested in reading Evernorth will list underwater. Then comes the vote. July 29, 2025 In Mainstream ← Previous post Next post →